<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813812</url>
  </required_header>
  <id_info>
    <org_study_id>DA6034_Gas_III (Version 4.3)</org_study_id>
    <nct_id>NCT01813812</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034</brief_title>
  <official_title>A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034 Compared With Rebamipide in Patients With Acute or Chronic Gastritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double-blinded, double-dummy, active-controlled, randomized, Phase III
      clinical trial to evaluate the efficacy and safety of DA-6034 and to demonstrate the
      non-inferiority of DA-6034 compared with Rebamipide in patients with acute or chronic
      gastritis. Subjects will receive 45mg, 90mg of DA-6034 and 300mg of Rebamipide, two tablets,
      three times a day for two weeks.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of erosions comparing the before and after the administration. For example, if the number of the erosion is 0, the score is 1 (normal).</measure>
    <time_frame>2 weeks</time_frame>
    <description>The scale is classified into 5 steps which are based on the severity of the improvement.
EX) noticable improvement: 4-&gt;1, 3-&gt;1, slight improvement: 4-&gt;3, 3-&gt;2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of erosions diagnosed by the gastroscope</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of the digestive symptoms (Scale of 1 to 5)</measure>
    <time_frame>2 weeks</time_frame>
    <description>the example of the symptoms are:
epigastralgia, heartburn, acid reflux, nausea, domperidone</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">492</enrollment>
  <condition>Acute Gastritis</condition>
  <condition>Chronic Gastritis</condition>
  <arm_group>
    <arm_group_label>DA-6034 45mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two tablets (of DA-6034 45mg) are administered for 2 continuous weeks, three times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-6034 90mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two tablets (of DA-6034 90mg) are administered for 2 continuous weeks, three times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rebamipide 300mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>two tablets (of Rebamipide 300mg) are administered for 2 continuous weeks, three times a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-6034</intervention_name>
    <arm_group_label>DA-6034 45mg</arm_group_label>
    <arm_group_label>DA-6034 90mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebamipide 300mg</intervention_name>
    <arm_group_label>Rebamipide 300mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with acute gastritis or chronic gastritis

          -  1 or more erosions found in the gastroscope examination

          -  Age should be: 20≤age≤75

        Exclusion Criteria:

          -  A patient with peptic ulcer and a gastroesophageal reflux disease.

          -  Received a medication including non-steroid anti-inflammatory drug 2 weeks before the
             initiation

          -  Had a surgery regarding gastroesophageal

          -  A patient with Zollinger-Ellison syndrome

          -  Had a medical history of a malignant tumor

          -  A patient who is currently taking anti-thrombotic drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun Chae Jung, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soo Heon Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University Yeouido St. Mary's Hopspital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seong Woo Jeon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang Woo Lee, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong Ho Lee, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kook Lae Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ju Yung Cho, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soonchunhyang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ki Myeong Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yongchan Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital, Yonsei University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang Yong Seol, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeong Seop Moon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong Sun Rew, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soo Taek Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chan Kook Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chosun University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Gyu Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sei Jin Youn, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hak Yang Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byung Chul Yoon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suck Chei Choi, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonkwang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ki Nam Shim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University Mokdong Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun Chae Jung, M.D., Ph.D.</last_name>
    <phone>82-2-2072-0694</phone>
    <email>snuhirb@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Chae Jung, M.D., Ph.D.</last_name>
      <phone>82-2-2072-0694</phone>
      <email>snuhirb@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2013</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>March 20, 2013</last_update_submitted>
  <last_update_submitted_qc>March 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Gastritis, Atrophic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rebamipide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

